Table 4.
The top 10 up-regulated genes in each type of myositis compared to normal biopsies.
| DM (All) | Anti-Mi2 | Anti-NXP2 | Anti-MDA5 | Anti-TIF1g | AS (Jo1) | IBM | IMNM (All) | Anti-HMGCR | Anti-SRP | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| gene | FC | qval | gene | FC | qval | gene | FC | qval | gene | FC | qval | gene | FC | qval | gene | FC | qval | gene | FC | qval | gene | FC | qval | gene | FC | qval | gene | FC | qval |
| ISG15 | 101 | 1.06E-91 | IFI6 | 62 | 2.6E-43 | ISG15 | 110 | 1.5E-55 | ISG15 | 163 | 1.2E-51 | ISG15 | 84 | 1.5E-47 | PSMB8 | 13 | 2.64E-25 | GBP2 | 7 | 1.27E-18 | SERPINA3 | 22 | 1.63E-28 | ACTC1 | 18 | 3.6E-31 | SERPINA3 | 24 | 1.8E-17 |
| IFI6 | 67 | 2.73E-80 | ISG15 | 67 | 5.9E-43 | IFI6 | 70 | 7.8E-48 | IFI6 | 72 | 2.6E-37 | IFI6 | 62 | 1.7E-43 | ACTC1 | 18 | 2.33E-23 | BIRC3 | 7 | 4.43E-18 | ACTC1 | 15 | 1.08E-27 | SERPINA3 | 20 | 5.8E-25 | ACTC1 | 12 | 9.8E-13 |
| MX1 | 29 | 2.58E-56 | MX1 | 32 | 1.9E-33 | RSAD2 | 23 | 2.1E-33 | ZFHX2 | 18 | 9.9E-25 | MX1 | 41 | 9.0E-39 | GBP2 | 7 | 1.11E-22 | PSMB8 | 9 | 1.70E-16 | CHRNA1 | 8 | 6.40E-21 | MYH3 | 17 | 8.1E-21 | HP | 18 | 1.6E-12 |
| RSAD2 | 18 | 1.25E-49 | OAS1 | 25 | 9.7E-28 | MX1 | 29 | 8.6E-33 | IFI35 | 30 | 2.3E-24 | MX2 | 22 | 6.9E-32 | SAA1 | 37 | 1.11E-22 | GBP1 | 11 | 3.50E-16 | IFITM10 | 9 | 3.20E-20 | CHRNA1 | 7 | 2.0E-19 | CHRNA1 | 9 | 2.7E-12 |
| MX2 | 17 | 2.48E-49 | MX2 | 18 | 1.2E-27 | IFIT2 | 22 | 5.6E-31 | ACP5 | 35 | 2.2E-23 | OAS1 | 29 | 3.8E-31 | SIK1 | 10 | 3.05E-21 | CCL13 | 20 | 4.96E-16 | TNC | 11 | 5.38E-20 | IFITM10 | 9 | 2.6E-19 | TNC | 11 | 6.7E-12 |
| OAS1 | 23 | 4.00E-48 | LY6E | 16 | 4.5E-26 | KLHDC7B | 65 | 1.1E-30 | SECTM1 | 26 | 1.0E-22 | IFITM1 | 12 | 2.7E-28 | NNMT | 14 | 9.65E-21 | ITGAL | 9 | 2.47E-15 | KRT80 | 13 | 1.35E-19 | TNNT2 | 16 | 1.7E-18 | DCLK1 | 7 | 6.7E-12 |
| IRF9 | 10 | 2.54E-43 | RSAD2 | 17 | 8.1E-26 | OAS1 | 26 | 4.7E-30 | ZBP1 | 42 | 1.6E-22 | RSAD2 | 18 | 2.0E-27 | MYH3 | 23 | 9.83E-21 | GBP5 | 17 | 3.95E-15 | TNNT2 | 15 | 1.35E-19 | ANKRD1 | 10 | 2.4E-18 | KRT80 | 13 | 6.7E-12 |
| IFITM1 | 10 | 8.62E-43 | CMPK2 | 15 | 2.2E-25 | OAS3 | 16 | 1.3E-26 | CLEC4GP1 | 19 | 5.4E-21 | TYMP | 30 | 2.0E-27 | GADD45A | 8 | 9.83E-21 | HLA-DQA1 | 13 | 2.41E-14 | MYH3 | 13 | 2.66E-19 | CSPG4 | 5 | 2.4E-18 | IFITM10 | 10 | 1.0E-11 |
| CMPK2 | 13 | 4.24E-42 | OAS3 | 16 | 3.6E-25 | HERC5 | 25 | 3.4E-26 | PSMB8 | 19 | 3.3E-20 | IFI44 | 18 | 4.1E-27 | GBP1 | 12 | 9.83E-21 | CD8A | 16 | 3.45E-14 | ANKRD1 | 10 | 2.04E-18 | TNC | 10.06 | 2.6E-18 | RUNX1 | 6.98 | 3.0E-11 |
| OAS3 | 14 | 2.27E-41 | KLHDC7B | 39 | 3.0E-23 | MX2 | 15 | 4.8E-26 | IFI27 | 18 | 2.2E-19 | DHX58 | 13 | 6.2E-27 | IFI30 | 16 | 1.02E-20 | HLA-DOA | 10 | 3.58E-14 | DCLK1 | 6 | 2.45E-18 | KRT80 | 11.97 | 9.9E-18 | TNNT2 | 13.81 | 3.3E-11 |
DM: dermatomyositis; AS: antisynthetase syndrome; IBM: inclusion body myositis; IMNM: inclusion body myositis; FC: fold-change; qval: adjusted p-value. The name and location of the genes is indicated in Supplementary Table 2.